10x Genomics, Inc.
For the period ended Jun 30, 2026. Filed Aug 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 7, 2026
TXG$65.05+9.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| June 30,2026 | December 31,2025 | |
|---|---|---|
| (Unaudited) | (Note 1) | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $502,512 | $473,966 |
| Marketable securities | 49,521 | 49,443 |
| Accounts receivable, net | 47,545 | 47,013 |
| Other receivables | 3,084 | 35,480 |
| Inventory | 52,616 | 56,341 |
| Prepaid expenses and other current assets | 19,393 | 22,208 |
| Total current assets | 674,671 | 684,451 |
| Property and equipment, net | 215,324 | 226,711 |
| Operating lease right-of-use assets | 56,685 | 60,450 |
| Goodwill | 6,918 | 4,511 |
| Intangible assets, net | 61,160 | 62,329 |
| Other noncurrent assets | 15,308 | 2,913 |
| Total assets | $1,030,066 | $1,041,365 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $20,694 | $12,733 |
| Accrued compensation and related benefits | 24,744 | 42,500 |
| Accrued expenses and other current liabilities | 30,377 | 39,971 |
| Deferred revenue | 23,610 | 23,902 |
| Operating lease liabilities | 12,015 | 10,985 |
| Contingent consideration, current | 7,069 | 23,363 |
| Total current liabilities | 118,509 | 153,454 |
| Contingent consideration, noncurrent | 2,991 | 1,237 |
| Operating lease liabilities, noncurrent | 66,781 | 73,376 |
| Deferred revenue, noncurrent | 9,683 | 10,501 |
| Other noncurrent liabilities | 6,556 | 6,471 |
| Total liabilities | 204,520 | 245,039 |
| Commitments and contingencies (Note 5) | ||
| Stockholders’ equity: | ||
| Preferred stock | — | — |
| Common stock | 2 | 2 |
| Additional paid-in capital | 2,367,459 | 2,306,690 |
| Accumulated deficit | (1,541,992) | (1,510,591) |
| Accumulated other comprehensive income | 77 | 225 |
| Total stockholders’ equity | 825,546 | 796,326 |
| Total liabilities and stockholders’ equity | $1,030,066 | $1,041,365 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.